New mechanisms involved in the pathogenesis of pituitary adenomas.

被引:0
|
作者
Giacomini, D
Paez-Pereda, M
Refojo, D
Nagashima, AC
Chervin, A
Goldberg, V
Arzt, E
机构
[1] Univ Buenos Aires, Dept Fisiol & Biol Celular & Mol, FCEN, RA-1428 Buenos Aires, DF, Argentina
[2] Hosp Santa Lucia, Buenos Aires, DF, Argentina
[3] Univ Buenos Aires, Fac Med, Inst Invest Med Alfredo Lanari, RA-1428 Buenos Aires, DF, Argentina
关键词
prolactinoma; c-Myc;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New mechanisms involved in the pathogenesis of pituitary adenomas. We studied Smad-4dn tumors generated from lactosomatotrophic GH3 cells stably transfected with a dominant negative form of Smad-4 (a bone morphogenetic protein-4, BMP-4, signal co-transducer) which had reduced tumorigenicity in nude mice, but had showed a late increase in tumor size. We found that they had lost in vivo the expression of Smad-4dn and had recovered c-Myc expression. In accordance, BMP-4 is overexpressed and stimulates the expression of c-Myc in human prolactinomas, but not in other human pituitary adenomas or normal pituitary. In adittion ICI 182,780 inhibited BMP-4 stimulated c-Myc expression and BMP-4 and 17beta-estradiol in combination had an additive effect on GH3 cell proliferation. Their action was inhibited by blocking BMP-4 with ICI 182,780 or 117beta-estradiol with Smad-4dn. Furthermore, co-immunoprecipitation studies demonstrate that Smad-4 physically interacts with the ERalpha/ERbeta. We show for the first time the role of BMP-4 in prolactinoma pathogenesis, involving a functional cross-talk BMP-4/E2.
引用
收藏
页码:147 / 150
页数:4
相关论文
共 50 条
  • [1] Homeoproteins and pituitary adenomas.
    Barlier, A
    PellegriniBouiller, I
    Gunz, G
    Jaquet, P
    Enjalbert, A
    ANNALES D ENDOCRINOLOGIE, 1997, 58 (01) : 3 - 10
  • [2] Unusual approaches for pituitary adenomas.
    Passagia, JG
    Gay, E
    Reyt, E
    Lebeau, J
    Favre, JJ
    Chirossel, JP
    NEUROCHIRURGIE, 1998, 44 (05) : 316 - 326
  • [3] Intracavernous extension of pituitary adenomas.
    Roux, FX
    Obreja, C
    Moussa, R
    Devaux, B
    Nataf, F
    Turak, B
    Page, P
    Meder, JF
    NEUROCHIRURGIE, 1998, 44 (05) : 344 - 351
  • [4] Medical treatment of pituitary adenomas.
    Thomopoulos, P
    NEUROCHIRURGIE, 1998, 44 (05) : 309 - 311
  • [5] Synaptophysin immunoreactivity of pituitary adenomas.
    Ilangovan, S
    Cyrkowicz, P
    Hazelrigg, R
    Clasen, R
    Thomas, C
    Reyes, MG
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (05): : 88 - 88
  • [6] Inhibin expression in pituitary adenomas.
    Gyure, KA
    Ioffe, OB
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (05): : 526 - 526
  • [7] Unilateral endonasal approach of pituitary adenomas.
    Guarnieri, J
    Moreau, S
    Cabal, P
    Valdazo, A
    Houtteville, JP
    NEUROCHIRURGIE, 1998, 44 (05) : 312 - 315
  • [8] Coexpression of TGFe and granulin A in pituitary adenomas.
    Halper, J
    Baterman, A
    Daniel, R
    Jung, C
    Lloyd, RV
    Scheithauer, BW
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (05): : 522 - 522
  • [9] New pathways in the pathogenesis of pituitary adenomas
    Nicholas F. Marko
    Robert J. Weil
    Nature Reviews Endocrinology, 2012, 8 : 572 - 573
  • [10] PITUITARY GLAND New pathways in the pathogenesis of pituitary adenomas
    Marko, Nicholas F.
    Weil, Robert J.
    NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (10) : 572 - 573